Shoreline is dedicated to creating next-generation cellular immunotherapies for cancer that overcome the current limitations of first-generation cell therapy products. Shoreline is building a pipeline of natural killer cell and macrophage-cell therapy candidates derived from its deep expertise in iPSC differentiation methods and genetic reprogramming of disease relevant pathways. Shoreline has strategic partnerships with Kite, a Gilead Company, and BeiGene, a global biotechnology company, Contract Development and Manufacturing Organization partnerships with well-established organizations, and is supported by high-quality investors.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
11/02/21	$140,000,000	Venture	Ally Bridge Group BeiGene Boxer Capital BVF Partners Commodore Capital Cormorant Asset Management Eventide Asset Management Kingdon Capital NS Investment Piper Heartland Healthcare Capital Superstring	undisclosed